Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Revenue (2020 - 2025)

Foghorn Therapeutics has reported Revenue over the past 6 years, most recently at $9.2 million for Q4 2025.

  • Quarterly results put Revenue at $9.2 million for Q4 2025, up 223.77% from a year ago — trailing twelve months through Dec 2025 was $30.9 million (up 36.75% YoY), and the annual figure for FY2025 was $30.9 million, up 36.75%.
  • Revenue for Q4 2025 was $9.2 million at Foghorn Therapeutics, up from $8.2 million in the prior quarter.
  • Over the last five years, Revenue for FHTX hit a ceiling of $17.5 million in Q3 2023 and a floor of $41000.0 in Q3 2021.
  • Median Revenue over the past 5 years was $5.5 million (2023), compared with a mean of $5.4 million.
  • Biggest five-year swings in Revenue: crashed 77.09% in 2021 and later surged 16080.49% in 2022.
  • Foghorn Therapeutics' Revenue stood at $713000.0 in 2021, then soared by 486.82% to $4.2 million in 2022, then skyrocketed by 37.88% to $5.8 million in 2023, then plummeted by 50.49% to $2.9 million in 2024, then skyrocketed by 223.77% to $9.2 million in 2025.
  • The last three reported values for Revenue were $9.2 million (Q4 2025), $8.2 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.